Found: 282
Select item for more details and to access through your institution.
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri<sup>®</sup>) Dosing: NOVA Phase IIIb Extension Study (Part 2).
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 5, p. 1385, doi. 10.1007/s40120-024-00647-0
- By:
- Publication type:
- Article
Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease.
- Published in:
- 2015
- By:
- Publication type:
- letter
Web-based assessment of Parkinson's prodromal markers identifies GBA variants.
- Published in:
- Movement Disorders, 2015, v. 30, n. 7, p. 1002, doi. 10.1002/mds.26249
- By:
- Publication type:
- Article
The new Bradykinesia Akinesia Incoordination (BRAIN) test: Preliminary data from an online test of upper limb movement.
- Published in:
- Movement Disorders, 2012, v. 27, n. 1, p. 157, doi. 10.1002/mds.23947
- By:
- Publication type:
- Article
Immunopathogenic mechanisms in tourette syndrome: A critical review.
- Published in:
- Movement Disorders, 2009, v. 24, n. 9, p. 1267, doi. 10.1002/mds.22504
- By:
- Publication type:
- Article
Antineuronal antibodies in Parkinson's disease.
- Published in:
- Movement Disorders, 2008, v. 23, n. 7, p. 958, doi. 10.1002/mds.21929
- By:
- Publication type:
- Article
Antineuronal antibody status and phenotype analysis in Tourette's syndrome.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Antibasal ganglia antibodies and PANDAS.
- Published in:
- Movement Disorders, 2005, v. 20, n. 1, p. 116, doi. 10.1002/mds.20310
- By:
- Publication type:
- Article
Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies.
- Published in:
- Movement Disorders, 2004, v. 19, n. 10, p. 1190, doi. 10.1002/mds.20126
- By:
- Publication type:
- Article
Choreic syndrome and coeliac disease: A hitherto unrecognised association.
- Published in:
- Movement Disorders, 2004, v. 19, n. 4, p. 478, doi. 10.1002/mds.10691
- By:
- Publication type:
- Article
Post-Streptococcal autoimmune neuropsychiatric disease presenting as paroxysmal dystonic choreoathetosis.
- Published in:
- Movement Disorders, 2002, v. 17, n. 4, p. 817, doi. 10.1002/mds.10169
- By:
- Publication type:
- Article
The bradykinesia akinesia incoordination test (BRAIN TEST©), an objective and user-friendly means to evaluate patients with Parkinsonism.
- Published in:
- Movement Disorders, 2000, v. 15, n. 4, p. 641, doi. 10.1002/1531-8257(200007)15:4<641::AID-MDS1007>3.0.CO;2-2
- By:
- Publication type:
- Article
VP167 Comparison Of Methodology In Mixed Treatment Comparisons Of Treatments For Multiple Sclerosis.
- Published in:
- 2017
- By:
- Publication type:
- Abstract
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 1, p. 63, doi. 10.1177/13524585231215268
- By:
- Publication type:
- Article
Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 9, p. 1068, doi. 10.1177/13524585231182702
- By:
- Publication type:
- Article
Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 9, p. 1070, doi. 10.1177/13524585231176732
- By:
- Publication type:
- Article
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 8, p. 979, doi. 10.1177/13524585231185247
- By:
- Publication type:
- Article
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 6, p. 719, doi. 10.1177/13524585231161494
- By:
- Publication type:
- Article
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 14, p. 2263, doi. 10.1177/13524585221114997
- By:
- Publication type:
- Article
Extended dosing of monoclonal antibodies in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 13, p. 2001, doi. 10.1177/13524585211065711
- By:
- Publication type:
- Article
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1591, doi. 10.1177/13524585221083194
- By:
- Publication type:
- Article
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1526, doi. 10.1177/13524585221076717
- By:
- Publication type:
- Article
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1219, doi. 10.1177/13524585211049392
- By:
- Publication type:
- Article
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 842, doi. 10.1177/13524585211061335
- By:
- Publication type:
- Article
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 111, doi. 10.1177/13524585211010294
- By:
- Publication type:
- Article
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 10, p. 1564, doi. 10.1177/1352458520971819
- By:
- Publication type:
- Article
Regarding: Nicotinic acetylcholine receptors α7 and α9 modify tobacco smoke risk for multiple sclerosis.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG MS study.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 6, p. 922, doi. 10.1177/1352458520936934
- By:
- Publication type:
- Article
Cognition and its relation to brain health in patients with MS: Response to letter.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 11, p. 1281, doi. 10.1177/1352458520907901
- By:
- Publication type:
- Article
Inclusion criteria used in trials of people with progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 3, p. 279, doi. 10.1177/1352458518803769
- By:
- Publication type:
- Article
World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 2, p. 153, doi. 10.1177/1352458519898340
- By:
- Publication type:
- Article
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 6, p. 819, doi. 10.1177/1352458518771875
- By:
- Publication type:
- Article
The Multiple Sclerosis Care Unit.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 5, p. 627, doi. 10.1177/1352458518807082
- By:
- Publication type:
- Article
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 14, p. 1862, doi. 10.1177/1352458518808189
- By:
- Publication type:
- Article
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 14, p. 1883, doi. 10.1177/1352458517735190
- By:
- Publication type:
- Article
e-Health and multiple sclerosis: An update.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 13, p. 1657, doi. 10.1177/1352458518799629
- By:
- Publication type:
- Article
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 13, p. 1725, doi. 10.1177/1352458517729464
- By:
- Publication type:
- Article
Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 12, p. 1594, doi. 10.1177/1352458517727603
- By:
- Publication type:
- Article
Psychiatric disorders in children with demyelinating diseases of the central nervous system.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 9, p. 1243, doi. 10.1177/1352458517719150
- By:
- Publication type:
- Article
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 2, p. 222, doi. 10.1177/1352458517690269
- By:
- Publication type:
- Article
Development of resistance to biologic therapies with reference to IFN-β.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Development of resistance to biologic therapies with reference to IFN-β.
- Published in:
- Rheumatology, 2012, v. 51, n. 4, p. 590, doi. 10.1093/rheumatology/ker445
- By:
- Publication type:
- Article
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 617, doi. 10.2165/00019053-200826070-00008
- By:
- Publication type:
- Article
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis.
- Published in:
- Clinical Drug Investigation, 2012, v. 32, n. 1, p. 15, doi. 10.2165/11593310-000000000-00000
- By:
- Publication type:
- Article
Inactive or moderately active human promoters are enriched for inter-individual epialleles.
- Published in:
- Genome Biology, 2013, v. 14, n. 5, p. 1, doi. 10.1186/gb-2013-14-5-r43
- By:
- Publication type:
- Article
No Evidence for Production of Intrathecal Immunoglobulin G against Acinetobacter or Pseudomonas in Multiple Sclerosis.
- Published in:
- European Neurology, 2005, v. 53, n. 1, p. 27, doi. 10.1159/000083715
- By:
- Publication type:
- Article